Opinicus Capital Inc. Buys Shares of 3,585 Eli Lilly and Company (NYSE:LLY)

Opinicus Capital Inc. bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,585 shares of the company’s stock, valued at approximately $2,090,000. Eli Lilly and Company accounts for about 2.1% of Opinicus Capital Inc.’s investment portfolio, making the stock its 11th largest position.

Other institutional investors have also added to or reduced their stakes in the company. Simon Quick Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after buying an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $363,000. Hartline Investment Corp boosted its holdings in shares of Eli Lilly and Company by 1.1% in the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock valued at $12,786,000 after buying an additional 248 shares in the last quarter. Meritage Portfolio Management boosted its holdings in shares of Eli Lilly and Company by 23.4% in the 4th quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock valued at $3,717,000 after buying an additional 1,208 shares in the last quarter. Finally, WASHINGTON TRUST Co boosted its holdings in shares of Eli Lilly and Company by 16.5% in the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after buying an additional 2,671 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent analyst reports. Barclays raised their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Truist Financial reiterated a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 22nd. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Finally, DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded up $8.64 during trading on Friday, hitting $733.51. 2,009,249 shares of the stock traded hands, compared to its average volume of 2,265,427. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company has a market cap of $696.95 billion, a price-to-earnings ratio of 126.47, a P/E/G ratio of 1.58 and a beta of 0.34. The company has a fifty day moving average price of $761.79 and a two-hundred day moving average price of $666.06. Eli Lilly and Company has a 52-week low of $380.77 and a 52-week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.09 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 12.51 EPS for the current year.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.